Assessing parameter uncertainty in small-n pharmacometric analyses: value of the log-likelihood profiling-based sampling importance resampling (LLP-SIR) technique
Open Access
- 4 April 2020
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 47 (3) , 219-228
Abstract
Assessing parameter uncertainty is a crucial step in pharmacometric workflows. Small datasets with ten or fewer subjects appear regularly in drug development and therapeutic use, but it is unclear which method to assess parameter uncertainty is preferable in such situations. The aim of this study was to (i) systematically evaluate the performance of standard error (SE), bootstrap (BS), log-likelihood profiling (LLP), Bayesian approaches (BAY) and sampling importance resampling (SIR) to assess parameter uncertainty in small datasets and (ii) to evaluate methods to provide proposal distributions for the SIR. A simulation study was conducted and the 0–95% confidence interval (CI) and coverage for each parameter was evaluated and compared to reference CIs derived by stochastic simulation and estimation (SSE). A newly proposed LLP-SIR, combining the proposal distribution provided by LLP with SIR, was included in addition to conventional SE-SIR and BS-SIR. Additionally, the methods were applied to a clinical dataset. The determined CIs differed substantially across the methods. The CIs of SE, BS, LLP and BAY were not in line with the reference in datasets with ≤ 10 subjects. The best alignment was found for the LLP-SIR, which also provided the best coverage results among the SIR methods. The best overall results regarding the coverage were provided by LLP and BAY across all parameters and dataset sizes. To conclude, the popular SE and BS methods are not suitable to derive parameter uncertainty in small datasets containing ≤ 10 subjects, while best performances were observed with LLP, BAY and LLP-SIR.Keywords
This publication has 15 references indexed in Scilit:
- Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membraneJournal of Antimicrobial Chemotherapy, 2019
- A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposureNaunyn-Schmiedeberg's Archives of Pharmacology, 2019
- Integration of Pharmacometric and Statistical Analyses Using Clinical Trial Simulations to Enhance Quantitative Decision Making in Clinical Drug DevelopmentStatistics in Biopharmaceutical Research, 2019
- Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic studyCritical Care, 2018
- Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resamplingJournal of Pharmacokinetics and Pharmacodynamics, 2016
- White Paper: Landscape on Technical and Conceptual Requirements and Competence Framework in Drug/Disease Modeling and SimulationCPT: Pharmacometrics & Systems Pharmacology, 2013
- Model-based Drug DevelopmentClinical Pharmacology & Therapeutics, 2007
- Evaluation of Uncertainty Parameters Estimated by Different Population PK Software and MethodsJournal of Pharmacokinetics and Pharmacodynamics, 2007
- Are Population Pharmacokinetic and/or Pharmacodynamic Models Adequately Evaluated?Clinical Pharmacokinetics, 2007
- Effect of uncertainty about population parameters on pharmacodynamics-based prediction of clinical trial powerContemporary Clinical Trials, 2005